Loading clinical trials...

Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma | Clinical Trials | Clareo Health

UNKNOWNPHASE1/PHASE2

Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma

NCT06279767•The First Affiliated Hospital with Nanjing Medical University

Summary

Glioblastoma, the most prevalent malignant tumor in the central nervous system, is characterized by high invasiveness and a propensity to recur, contributing to a relatively elevated mortality rate. Patients diagnosed with high-grade glioblastomas typically experience a median survival period of less than 14 months. Presently, the standard treatment for glioblastoma involves surgical resection combined with postoperative radiotherapy and chemotherapy, with postoperative chemotherapy playing a pivotal role in enhancing patient prognosis. Temozolomide (TMZ), a cutting-edge oral alkylating agent known for its advantageous properties, including easy traversal of the blood-brain barrier, induces DNA alkylation in tumor cells, fostering apoptosis. Currently, it serves as a frontline medication for postoperative chemotherapy in glioblastoma. However, clinical resistance to TMZ chemotherapy significantly hampers its efficacy in later stages. We have recently discovered and validated that 5-aminoimidazole-4-carboxamide (AICA), derived from TMZ, can transform into 5-aminoimidazole-4-carboxamide ribonucleotide-5-phosphate (AICAR) in GBM cells. Hypoxanthine phosphoribosyltransferase 1 (HPRT1) has been identified as the catalyst for the AICA reaction, generating AICAR. AICAR acts as an endogenous activator of AMP-activated protein kinase (AMPK), fostering chemoresistance in glioblastoma through the activation of the AMPK signaling pathway. 6-mercaptopurine (6-MP) competes effectively to inhibit HPRT1 activity, thereby impeding TMZ-induced AMPK activation and significantly heightening glioblastoma cell sensitivity to TMZ. In this project, we propose an innovative strategy involving the combination of 6-MP with TMZ for the treatment of glioblastoma.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age between 18 and 65, no gender restrictions.
•2. Histologically confirmed glioblastoma as the primary tumor after surgery.
•3. Patients with recurrent glioblastoma confirmed by MRI after standard treatment (surgery, Stupp regimen) failure, supported by RANO criteria evaluation.
•4. At least one measurable intracranial tumor lesion according to RANO criteria.
•5. No prior treatment with 6-mercaptopurine or similar drugs.
•6. General condition assessed by Karnofsky Performance Status (KPS) score ≥ 60.
•7. Normal bone marrow function: white blood cell count ≥ 3.5 × 10\^9/L, neutrophil count ≥ 2.0 × 10\^9/L, hemoglobin count ≥ 90 g/L, platelet count ≥ 80 × 10\^9/L.
•8. Normal organ functions such as heart and lung, and no severe internal diseases.
•9. Willing to sign an informed consent form, good compliance, able to attend regular follow-ups, and voluntarily agree to comply with the study protocol.

Exclusion Criteria

•1. Participants who do not consent.
•2. Vulnerable populations such as pregnant women, children, and adolescents.
•3. No history of or concurrent malignancy within the past 5 years.
•4. Abnormal liver function (total bilirubin \> 1.5 times the upper limit of normal, ALT/AST \> 2 times the upper limit of normal).
•5. Impaired kidney function (serum creatinine \> 1.5 times the upper limit of normal).
•6. Presence of organic heart disease leading to clinical symptoms or cardiac dysfunction (NYHA ≥ Grade 2).
•7. Factors significantly affecting oral drug absorption, such as difficulty swallowing, intestinal obstruction, etc.

Locations (1)

Department of Neurosurgery of The First Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, China

Key Dates

Start Date

July 1, 2022

Primary Completion Date

July 1, 2025

Completion Date

July 31, 2025

Last Updated

February 28, 2024

Enrollment

ESTIMATED participants

Conditions

GlioblastomaCancerTemozolomide

Interventions

6-mercaptopurine

DRUG

Contacts

Yongping You, DD

CONTACT

13770694258 YYPL3@sohu.com

En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device

NCT04235764

Bladder Cancer

View study

RECRUITINGPHASE1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 28, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma

Inclusion Criteria

Exclusion Criteria

En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer